Kk Bcj-94 Drug Patent Portfolio
Kk Bcj-94 owns 1 orange book drug protected by 8 US patents Given below is the list of Kk Bcj-94's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US12194025 | Pharmaceutical composition for oral administration of edaravone and method of administering same | 12 Nov, 2041 | Active |
US12310946 | Pharmaceutical composition for oral administration of edaravone and method of administering same | 12 Nov, 2041 | Active |
US10987341 | Edaravone suspension for oral administration | 01 Nov, 2039 | Active |
US11241416 | Edaravone suspension for oral administration | 01 Nov, 2039 | Active |
US11478450 | Edaravone suspension for oral administration | 01 Nov, 2039 | Active |
US11826352 | Edaravone suspension for oral administration | 01 Nov, 2039 | Active |
US11957660 | Edaravone suspension for oral administration | 01 Nov, 2039 | Active |
US12285409 | Edaravone suspension for oral administration | 01 Nov, 2039 | Active |
Latest Legal Activities on Kk Bcj-94's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Kk Bcj-94.
Activity | Date | Patent Number |
---|---|---|
![]() | ||
Patent eGrant Notification | 16 Apr, 2024 | US11957660 |
Recordation of Patent Grant Mailed
Critical
| 16 Apr, 2024 | US11957660 |
Recordation of Patent eGrant | 16 Apr, 2024 | US11957660 |
Patent Issue Date Used in PTA Calculation
Critical
| 16 Apr, 2024 | US11957660 |
Email Notification
Critical
| 16 Apr, 2024 | US11957660 |
Mail Patent eGrant Notification | 16 Apr, 2024 | US11957660 |
Email Notification
Critical
| 28 Mar, 2024 | US11957660 |
Issue Notification Mailed
Critical
| 27 Mar, 2024 | US11957660 |
Dispatch to FDC | 21 Mar, 2024 | US11957660 |
Application Is Considered Ready for Issue
Critical
| 21 Mar, 2024 | US11957660 |
Issue Fee Payment Verified
Critical
| 20 Mar, 2024 | US11957660 |
Issue Fee Payment Received
Critical
| 20 Mar, 2024 | US11957660 |
Electronic Review
Critical
| 20 Dec, 2023 | US11957660 |
Email Notification
Critical
| 20 Dec, 2023 | US11957660 |
Mail Notice of Allowance
Critical
| 20 Dec, 2023 | US11957660 |
Kk Bcj-94's Family Patents

Kk Bcj-94 Drug List
Given below is the complete list of Kk Bcj-94's drugs and the patents protecting them.
1. Radicava Ors
Radicava Ors is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US12194025 | Pharmaceutical composition for oral administration of edaravone and method of administering same |
12 Nov, 2041
(16 years from now)
| Active |
US12310946 | Pharmaceutical composition for oral administration of edaravone and method of administering same |
12 Nov, 2041
(16 years from now)
| Active |
US10987341 | Edaravone suspension for oral administration |
01 Nov, 2039
(14 years from now)
| Active |
US11241416 | Edaravone suspension for oral administration |
01 Nov, 2039
(14 years from now)
| Active |
US11478450 | Edaravone suspension for oral administration |
01 Nov, 2039
(14 years from now)
| Active |
US11826352 | Edaravone suspension for oral administration |
01 Nov, 2039
(14 years from now)
| Active |
US11957660 | Edaravone suspension for oral administration |
01 Nov, 2039
(14 years from now)
| Active |
US12285409 | Edaravone suspension for oral administration |
01 Nov, 2039
(14 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Radicava Ors's drug page